JPRN-jRCT1091220012已完成2 期
An open-label clinical trial of the combination treatment of tacrolimus and corticosteroid in polymyositis/dermatomyositis patients with interstitial pneumonitis, with comparison against corticosteroid-treated historical controls - IMPPACT
IMPPACT study central office0 个研究点目标入组 25 人开始时间: 2007年7月5日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 25
研究概览
简要总结
The 52-week survival rate with the combination treatment (N= 26) was 88.0% (95% CI, 67.3, 96.0). Safety profiles of the combination treatment were consistent with those known for tacrolimus and high-dose glucocorticoids individually. Serious adverse events occurred in 11 patients (44.0%), which included four opportunistic infections. Only 16 patients, including only 1 deceased patient, were registered as historical controls, which precluded meaningful comparative analysis against the clinical trial patients. Our study provided findings which suggest that initial treatment with tacrolimus and glucocorticoids may improve short-term mortality of polymyositis/dermatomyositis-interstitial pneumonia patients with manageable safety profiles. This was the first prospective clinical investigation conducted according to the Good Clinical Practice Guideline of the International Conference on Harmonization for the treatment of this potentially life-threatening disease.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 16age old 至 < 75age old（—）
- 性别
- All
入选标准
- •Experimental treatment group
- •(1) Diagnosis of definite or probable polymyositis or dermatomyositis by criteria of Bohan et al, or of clinically-amyopathic dermatomyositis by the definition proposed by Sontheimer et al
- •(2) High-resolution CT findings consistent with interstitial pneumonitis, confirmed by a radiologist. If consolidation is the only abnormal findings, the patient must have pathologically documented evidence of interstitial pneumonitis of other hitological type than cryptogenic organizing pneumonia/bronchiolitis obliterans organizing pneumonia (the patient could have more than one histological type including cryptogenic organizing pneumonia/bronchiolitis obliterans organizing pneumonia)
- •(3) Meet two or more of the following criteria (must include 1)
- •1. Serum KL-6 above the upper normal limit
- •2. Presence of dyspnea on exertion (grade 2 on the Magnitude of Task component of the Mahler Modified Dyspnea Index
- •3. PaO2 of less than 80 mmHg while breathing ambient air at rest, not accompanied by abnormal increase of PaCO2
- •4. Vital capacity < 80% predicted, or diffusing capacity for carbon monoxide < 65% predicted
- •5. Meet at least one of the following condition over the 12-week period (84 days) prior to the initiation of the study drug
- •- Decrease in either % forced vital capacity or % diffusing capacity for carbon monoxide of 10% or more
- •- Worsening of interstitial pneumonitis findings by chest CT, confirmed by a radiologist
- •(4) 16 to 74 years of age
- •Historical control group
- •(1) Diagnosis of definite or probable polymyositis or dermatomyositis by criteria of Bohan et al, or of clinically-amyopathic dermatomyositis by the definition proposed by Sontheimer et al
- •(2) High-resolution CT findings consistent with interstitial pneumonitis, confirmed by a radiologist. If consolidation is the only abnormal findings, the patient must have pathologically documented evidence of interstitial pneumonitis of other hitological type than cryptogenic organizing pneumonia/bronchiolitis obliterans organizing pneumonia (the patient could have more than one histological type including cryptogenic organizing pneumonia/bronchiolitis obliterans organizing pneumonia)
- •(3) Meet two or more of the following criteria (must include 1)
- •1. Serum KL-6 above the upper normal limit
- •2. Presence of dyspnea on exertion (grade 2 on the Magnitude of Task component of the Mahler Modified Dyspnea Index
- •3. PaO2 of less than 80 mmHg while breathing ambient air at rest, not accompanied by abnormal increase of PaCO2
- •4. Vital capacity < 80% predicted, or diffusing capacity for carbon monoxide < 65% predicted
- •5. Meet at least one of the following condition over the 12-week period (84 days) prior to the initiation of the study drug
- •- Decrease in either % forced vital capacity or % diffusing capacity for carbon monoxide of 10% or more
- •- Worsening of interstitial pneumonitis findings by chest CT, confirmed by a radiologist
- •(4) Use of corticosteroids at doses equivalent to between 0.6 to 1.0mg/kg/day of prednisolone for 14 days or longer to treat interstitial pneumonitis on or after the day when the inclusion criteria (3) was met (up to two courses of pulse IV corticosteroid therapy within the first 28 days are allowed)
- •(5) 16 to 74 years of age
排除标准
- •Experimental treatment group
- •(1) Use of corticosteroids at doses equivalent to or higher than prednisolone 0.6mg/kg/day within 4 weeks (28 days) prior to the initiation of the study drug
- •(2) Use of immunosuppressive agents other than corticosteroids within 12 weeks (84 days) prior to the initiation of the study drug
- •(3) Could not exclude the following conditions on clinical ground: drug-induced pneumonitis, occupational lung disease, hypersensitivity pneumonitis, radiation-induced lung injury
- •(4) Presence of end-stage interstitial pneumonitis as identified on the basis of a vital capacity < 45% predicted, diffusing capacity for carbon monoxide < 30% predicted, or lung CT with predominantly honeycombing appearance
- •(5) Presence of pancreatitis
- •(6) Presence of diabetes mellitus with the exception of glucocorticoid-induced one that is well-controlled (HbA1c < 6.5%)
- •(7) Serum creatinine of 1.5 mg/dL or above
- •(8) Presence of liver dysfunction (AST(GOT) or ALT (GPT) greater than 2.5 times the upper limit of normal) with the exception of the one that is considered to be due to myositis and is accompanied by the elevation of muscle enzymes above the upper limit of normal
- •(9) Serum potassium above the upper limit of normal
- •(10) Presence of ischemic heart disease, arrhythmia requiring treatment, congestive heart failure, or pulmonary hypertension requiring treatment
- •(11) Presence or history of malignancy with the exception of those without relapse off treatment for 5 years or longer
- •(12) Presence of serious active infection
- •(13) Presence of active hepatitis B, hepatitis C, or HIV infection
- •(14) History of severe drug hypersensitivity reaction
- •(15) Patients who are pregnant or breast-feeding, or patients who intend to or whose spouses intend to conceive during the course of the study, including the follow-up period
- •(16) Participation in another clinical trial or post-marketing clinical study within 26 weeks (182 days) prior to screening
- •(17) Other medical condition which, in the investigator's judgment, may be associated with increased risk to the subject or may interfere with study assessments or outcomes
- •Historical control group
- •(1) Use of immunosuppressive agents other than corticosteroids within 12 weeks (84 days) prior to or 2 weeks (14 days) after the corticosteroid treatment as defined by the inclusion criteria (4) is initiated
- •(2) Could not exclude the following conditions on clinical ground: drug-induced pneumonitis, occupational lung disease, hypersensitivity pneumonitis, radiation-induced lung injury
- •(3) Presence of end-stage interstitial pneumonitis as identified on the basis of a vital capacity < 45% predicted, diffusing capacity for carbon monoxide < 30% predicted, or lung CT with predominantly honeycombing appearance
- •(4) Presence of pancreatitis
- •(5) Presence of diabetes mellitus with the exception of glucocorticoid-induced one that is well-controlled (HbA1c < 6.5%)
- •(6) Serum creatinine of 1.5 mg/dL or above
- •(7) Presence of liver dysfunction (AST(GOT) or ALT (GPT) greater than 2.5 times the upper limit of normal) with the exception of the one that is considered to be due to myositis and is accompanied by the elevation of muscle enzymes above the upper limit of normal
- •(8) Serum potassium above the upper limit of normal
- •(9) Presence of ischemic heart disease, arrhythmia requiring treatment, congestive heart failure, or pulmonary hypertension requiring treatment
- •(10) Presence or history of malignancy with the exception of those witho
研究者
相似试验
已完成
3 期
Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential HypertensionEssential HypertensionNCT01237873Novartis Pharmaceuticals150
已完成
2 期
Phase 2 study evaluating the efficacy and safety of the combination of Bendamustine, Rituximab and Dexamethazone (RBenda-D) for treatment of CD20-positive relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.Relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.JPRN-UMIN000008145Kyoto Prefectural University of Medicine/K-LSG33
已完成
3 期
A 26-week treatment, randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy, safety and tolerability of NVA237 in patients with chronic obstructive pulmonary disease (CNVA237A2304)chronic obstructive pulmonary diseaseCOPD10038716NL-OMON34669ovartis32
进行中（未招募）
不适用
A 26-week treatment, randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy, safety and tolerability of NVA237 in patients with chronic obstructive pulmonary disease.chronic obstructive pulmonary disease (COPD)MedDRA version: 12.0Level: LLTClassification code 10010952Term: COPDEUCTR2009-013504-32-NLovartis Pharma Services AG800
已完成
2 期
Safety and Efficacy Study of Combination Therapy With Cetuximab and FOLFOX4 in Patients With Colorectal CancerColorectal CancerNCT00202787Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)136